SEKISUI CHEMICAL: Filing of Lawsuit Seeking Injunction and Damages for Patent Infringement in Relation to PVB Interlayer in Germany and Korea
The High Performance Plastics Company (President: Ikusuke Shimizu) of SEKISUI CHEMICAL CO., LTD. (President and Representative Director: Keita Kato; hereinafter “SEKISUI CHEMICAL”) has filed lawsuits for infringement of its European patent 2 017 237 (“EP ’237”), European patent 3 208 247 (“EP ’247”), European patent 3 357 888 (“EP ’888”) and European patent 3 392 222 (“EP ’222”) against Kuraray Europe GmbH (hereinafter “Kuraray Europe”), a subsidiary of Kuraray Co., Ltd., as the defendant before the District Courts Munich I (docket No. 7 O 12401/24, docket No. 7 O 12476/24 and docket No. 7 O 12477/24) and Mannheim (docket No. 2 O 92/24) in Germany.
The lawsuits based on EP ’237 and EP ’247 relating to sound control properties of a PVB Interlayer and based on EP ’888 relating to shrinkage properties of a PVB Interlayer owned by SEKISUI CHEMICAL and asserted before the District Court Munich I, seek, inter alia, injunctions against the manufacture and offering for sale etc. of “‘Trosifol’ The Wedge Acoustic” and “‘Trosifol’ The Wedge Acoustic Shadeband” sound insulation wedge products manufactured and offered for sale by Kuraray Europe in Germany, as well as, inter alia, declaratory judgments on liability for damages.
The lawsuit based on EP ’222 relating to glossiness for a PVB Interlayer, owned by SEKISUI CHEMICAL and asserted before the District Court Mannheim, seeks, inter alia, an injunction against the manufacture and offering for sale etc. of “‘Trosifol’ The Wedge Acoustic” and “‘Trosifol’ The Wedge Acoustic Shadeband” sound insulation wedge products manufactured and offered for sale by Kuraray Europe in Germany, as well as, inter alia, a declaratory judgement on liability for damages.
SEKISUI CHEMICAL has filed a patent infringement lawsuit against Kuraray Korea Ltd. (hereinafter “Kuraray Korea”), a subsidiary of Kuraray Co., Ltd., as the defendant in the Seoul Central District Court of Korea.
Based on the Korean patent for PVB Interlayer owned by SEKISUI CHEMICAL, the lawsuit seeks an injunction against the manufacture and sale, etc. in Korea of ‘Trosifol’ The Wedge Acoustic and ‘Trosifol’ The Wedge Acoustic Shadeband, sound insulation wedge products manufactured and sold by Kuraray Korea, and damages.
SEKISUI CHEMICAL regards its intellectual property rights as an important management resource. It will take strict action in cases where it determines that SEKISUI CHEMICAL Group’s intellectual property rights have been infringed.
About SEKISUI CHEMICAL Group
Headquartered in Japan, SEKISUI CHEMICAL CO., LTD. (TSE: 4204) and its subsidiaries make up the SEKISUI CHEMICAL Group. 26,000 employees in over 156 companies throughout 20 countries and regions aim to contribute to improving the lives of the people of the world and the earth’s environment. Thanks to a history of innovation, dedication and a pioneering spirit, SEKISUI CHEMICAL now holds leading positions in its three diverse business divisions as well as top global market share in interlayer film, foam products, conductive particles and more.
Disclaimer
This press release may contain forward-looking statements. Such forward-looking statements are based on current expectations and beliefs and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements due to changes in global economic, business, competitive market and regulatory factors.
View source version on businesswire.com: https://www.businesswire.com/news/home/20241101799415/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Study from UK’s Largest Virtual ADHD Service Validates Role of Objective Testing in Delivering Personalized, High-Quality Remote ADHD Care10.5.2025 12:45:00 CEST | Press release
Data presented at ADHD World Congress highlights how QbCheck supports diagnostic accuracy and individualized treatment monitoring, enabling efficient and robust care in virtual settings. News Summary: New findings show significant improvements in access, clinician confidence, symptom tracking, and individualized care using objective testing. The study underscores the importance of scalable, evidence-based tools, as many countries, including both the UK and the US, face rising demand for ADHD diagnosis and treatment. The study revealed significant improvements post-treatment, validating clinical practice and better clinician-patient alignment. As demand for virtual ADHD care increases, findings from a new study conducted with ADHD 360, the UK’s largest evidence-based digital service specializing in ADHD diagnosis and treatment, reveal how objective ADHD diagnostic and monitoring technology improves patient outcomes and clinical certainty. Presented at the 2025 ADHD World Congress in Pra
Ant International Partners with Barclays on Global Treasury Management with Proprietary AI-Powered FX Model9.5.2025 15:57:00 CEST | Press release
The Time-Series Transformer AI FX Model forecasts cashflow and FX exposure with more than 90% accuracy, helping businesses reduce FX-related fees Ant International has entered a partnership with leading UK bank Barclays to enhance efficiency and resilience in global treasury management for businesses. Under the partnership, the two sides will combine innovative solutions, including Ant’s proprietary Time-Series Transformer (TST) AI FX Model, to help businesses reduce FX-related costs and risks against global volatilities. At the initial stage of the collaboration, Ant International has successfully completed the first batch of its intra-group FX transactions with Barclays. Ant International’s TST Model is a transformer architecture-based big data model with close to 2 billion parameters. By integrating the latest time series forecasting algorithms, the TST Model predicts patterns over time. Ant also created new pre-training and Supervised Fine-Tuning (SFT) frameworks to train the model
IFF Completes Divestiture of Nitrocellulose Business9.5.2025 14:00:00 CEST | Press release
IFF (NYSE: IFF) today announced that it has completed the divestiture of its nitrocellulose business, including Walsrode Industrial Park in lower Saxony, Germany, to Czechoslovak Group (CSG). The business manufactures nitrocellulose strictly for industrial purposes, serving customers primarily in coatings and printing inks, and had been part of IFF’s Pharma Solutions business unit. “The divestiture of our nitrocellulose business builds upon our deleveraging journey and enables us to focus on our core businesses,” said Erik Fyrwald, IFF CEO. “I’d like to thank our nitrocellulose colleagues for their dedication and wish them continued success as part of CSG.” Welcome to IFF At IFF (NYSE: IFF), we make joy through science, creativity and heart. As the global leader in flavors, fragrances, food ingredients, health and biosciences, we deliver groundbreaking, sustainable innovations that elevate everyday products—advancing wellness, delighting the senses and enhancing the human experience.Le
Monument Re Transfers €1.4bn Greycastle Portfolio to RGA and Strengthens European Life Insurance Consolidation Platform9.5.2025 14:00:00 CEST | Press release
Monument Re Limited (“Monument”) announces today that it has transferred a legacy €1.4bn reinsurance portfolio, comprising annuity and other life insurance liabilities acquired as part of the 2020 Greycastle transaction, to RGA Americas Reinsurance Company, Ltd. (“RGA”). This transaction releases capital resources that Monument will redirect to its core strategy of consolidation in European life insurance markets. The transaction completed on 2May 2025 following approval by the Boards of Directors of both Monument and RGA and non-objection from the Bermuda Monetary Authority. Monument has taken significant steps in recent months to strengthen its business operations by consolidating its European group support functions in Dublin and by aligning with the recently strengthened regulatory regime in Bermuda. With its strong financial position and best in class capabilities in the Group, Monument remains ideally positioned to build on its success to date and grow its European footprint, del
CPAC Systems AB Announces Strategic Minority Investment in Flying Fish9.5.2025 12:33:00 CEST | Press release
Accelerating the shift toward sustainable and intelligent water mobility CPAC Systems AB, a leader in advanced control systems and embedded vessel and commercial vehicle technology, today announced a strategic minority investment in Flying Fish Maritime Innovations B.V., a pioneer in advanced shared water mobility solutions and robust, cost-effective hydrofoil technology. The investment underscores both companies’ commitment to redefining water-based transportation through innovation, sustainability, and seamless integration. It marks the beginning of a deeper collaboration aimed at enabling smarter, cleaner, and more connected mobility on the water — for both recreational and commercial applications. “We are thrilled to support Flying Fish and their impressive work in redefining water mobility,"saidMarcus Wingolf, CEO of CPAC Systems. "Our investment in Flying Fish represents a strategic alignment of our technical proficiencies and innovative ambitions. This partnership opens exciting
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom